We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026
Read MoreHide Full Article
Key Takeaways
IRWD stock jumped 26.7% on Jan. 2 after the company issued upbeat revenue guidance for 2026.
Ironwood expects $450-$475M in 2026 revenues and more than $300M in adjusted EBITDA.
IRWD to start a phase III study on apraglutide in 1H26 after aligning with the FDA on study design.
Shares of Ironwood Pharmaceuticals (IRWD - Free Report) were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026. The company maintained its revenue guidance for full-year 2025, which it had provided in November 2025.
Ironwood’s sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating functional constipation (“FC”) in children and adolescents aged six to 17 years.
In the past six months, shares of Ironwood have skyrocketed 498.9% compared with the industry’s increase of 6%.
Image Source: Zacks Investment Research
IRWD's 2026 Guidance
Reflecting the strong demand for Linzess, especially during the second half of 2025, Ironwood expects total revenues of $450 million to $475 million in 2026. The revenue outlook for 2026 indicates an increase of 54% year over year at the midpoint compared with 2025. This likely boosted investors' optimism and resulted in the stock price appreciation on Jan. 2.
The company also expects to deliver an adjusted EBITDA of more than $300 million in 2026, reflecting effective cost management.
Also, with effect from Jan. 1, 2026, Linzess’ list price has been reduced to help maintain patient access. As a result, management expects Linzess' net sales to increase year over year in 2026, driven by the removal of inflation-related statutory rebates across channels.
IRWD's Key Pipeline Updates
Ironwood also outlined key pipeline goals for 2026. The company is developing its next-generation GLP-2 analog, apraglutide, for treating patients with short bowel syndrome (“SBS”) with intestinal failure (“IF”) who are dependent on parenteral support (PS).
IRWD recently met with the FDA to align on a confirmatory phase III study design of apraglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF). The company remains on track to initiate a confirmatory study on apraglutide for the given indication in the first half of 2026. More updates on this study are expected to be announced during Ironwood’s fourth-quarter and full-year 2025 results.
Ironwood acquired the rights to develop and commercialize apraglutide following the acquisition of VectivBio in June 2023.
The company continues to expect revenues of $290-$310 million for 2025, as well as deliver an adjusted EBITDA of more than $135 million. Ironwood ended the fourth quarter of 2025 with more than $200 million in cash and cash equivalents.
In the past 60 days, estimates for CorMedix’s 2026 earnings per share (EPS) have moved up from $2.49 to $2.88. CRMD stock has increased 6.5% in the past six months.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2026 EPS have moved up from $7.81 to $8.08. ANIP stock has rallied 20.8% in the past six months.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 21.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026
Key Takeaways
Shares of Ironwood Pharmaceuticals (IRWD - Free Report) were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026. The company maintained its revenue guidance for full-year 2025, which it had provided in November 2025.
Ironwood’s sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating functional constipation (“FC”) in children and adolescents aged six to 17 years.
In the past six months, shares of Ironwood have skyrocketed 498.9% compared with the industry’s increase of 6%.
Image Source: Zacks Investment Research
IRWD's 2026 Guidance
Reflecting the strong demand for Linzess, especially during the second half of 2025, Ironwood expects total revenues of $450 million to $475 million in 2026. The revenue outlook for 2026 indicates an increase of 54% year over year at the midpoint compared with 2025. This likely boosted investors' optimism and resulted in the stock price appreciation on Jan. 2.
The company also expects to deliver an adjusted EBITDA of more than $300 million in 2026, reflecting effective cost management.
Also, with effect from Jan. 1, 2026, Linzess’ list price has been reduced to help maintain patient access. As a result, management expects Linzess' net sales to increase year over year in 2026, driven by the removal of inflation-related statutory rebates across channels.
IRWD's Key Pipeline Updates
Ironwood also outlined key pipeline goals for 2026. The company is developing its next-generation GLP-2 analog, apraglutide, for treating patients with short bowel syndrome (“SBS”) with intestinal failure (“IF”) who are dependent on parenteral support (PS).
IRWD recently met with the FDA to align on a confirmatory phase III study design of apraglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF). The company remains on track to initiate a confirmatory study on apraglutide for the given indication in the first half of 2026. More updates on this study are expected to be announced during Ironwood’s fourth-quarter and full-year 2025 results.
Ironwood acquired the rights to develop and commercialize apraglutide following the acquisition of VectivBio in June 2023.
The company continues to expect revenues of $290-$310 million for 2025, as well as deliver an adjusted EBITDA of more than $135 million. Ironwood ended the fourth quarter of 2025 with more than $200 million in cash and cash equivalents.
Ironwood Pharmaceuticals, Inc. Price
Ironwood Pharmaceuticals, Inc. price | Ironwood Pharmaceuticals, Inc. Quote
IRWD’s Zacks Rank & Other Key Picks
Ironwood currently carries a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) , both sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s 2026 earnings per share (EPS) have moved up from $2.49 to $2.88. CRMD stock has increased 6.5% in the past six months.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2026 EPS have moved up from $7.81 to $8.08. ANIP stock has rallied 20.8% in the past six months.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 21.24%.